Considering the commonality of tyramine in daily life and therefore its better potential for clinical transformation, we then applied Tyra into the in vitro coculture system and found that Tyra could efficiently reverse the downregulation of surface MHC-I and OVA antigen in Map3k1-mut tumor cells, thus enhancing the activation of CD8+ T cells in the coculture system (Supplemental Figure 10, G–J). The gene discussed is MAP3K1; the disease is neoplasm.